Temporal and spatial distribution of trace metals in the Rufiji delta mangrove, Tanzania

Spatial and temporal distribution of trace metals and their cycling is a key issue for understanding the ongoing biogeochemical processes in coastal environments. Sediment cores were collected from six different sampling locations from the Rufiji delta mangrove forests in southeastern coastal Tanzania that are perceived to be impacted by urban development and agricultural activities in the catchment, and pollution in upstream sections of the Rufiji River. The chronology and sediment accumulation rates at these sampling sites were derived based on the distribution of Pb-210(excess) method. The trace metals (As, Cd, Cr, Cu, Ni, Pb, and Zn) were sequentially extracted as per the BCR method and analyzed. The results indicate that the mass accumulation rates range from 0.40 g cm(-2) year(-1) (cores NR3 and NR4) to 1.75 g cm(-2) year(-1) (core SR1). Trace metals in the cores are mainly associated with the residual phase and their abundances in sediments are ranked as Cr amp;gt; Zn amp;gt; Ni amp;gt; Cu amp;gt; Pb amp;gt; Cd. The results imply that trace metals in the Rufiji delta mangroves are mainly of crustal origin, and they are less sensitive to weathering. Further, these metals are least available for uptake by plants and they pose limited threat to the biota.Funding Agencies|Swedish Research Link project-Africa [348-211-7408]; Western Indian Ocean Marine Science Association (WIOMSA); MARG 2</p

BESPOKE IO protocol: A multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours

INTRODUCTION: Immunotherapy (IO) has transformed the treatment paradigm for a wide variety of solid tumours. However, assessment of response can be challenging with conventional radiological imaging (eg, iRECIST), which do not precisely capture the unique response patterns of tumours treated with IO. Emerging data suggest that circulating tumour DNA (ctDNA) can aid in response assessment in patients with solid tumours receiving IO. The short half-life of ctDNA puts it in a unique position for early treatment response monitoring. The BESPOKE IO study is designed to investigate the clinical utility of serial ctDNA testing to assess treatment response using a tumour-informed, bespoke ctDNA assay (Signatera) and to determine its impact on clinical decision-making with respect to continuation/discontinuation, or escalation/de-escalation of immunotherapy in patients with advanced solid tumours. METHODS AND ANALYSIS: The BESPOKE IO is a multicentre, prospective, observational study with a goal to enroll over 1500 patients with solid tumours receiving IO in up to 100 US sites. Patients will be followed for up to 2 years with serial ctDNA analysis, timed with every other treatment cycle. The primary endpoint is to determine the percentage of patients who will have their treatment regimen changed as guided by post-treatment bespoke ctDNA results along with standard response assessment tools. The major secondary endpoints include progression-free survival, overall survival and overall response rate based on the ctDNA dynamics. ETHICS AND DISSEMINATION: The BESPOKE IO study was approved by the WCG Institutional Review Board (Natera-20-043-NCP BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO)) on 22 February 2021. Data protection and privacy regulations will be strictly observed in the capturing, forwarding, processing and storing patients\u27 data. Natera will approve the publication of any study results in accordance with the site-specific contract. TRIAL REGISTRATION NUMBER: NCT04761783